Cubist Systematic Strategies’s Carisma Therapeutics CARM Stock Holding History

Cubist Systematic Strategies’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-791	Closed	-$9.64K	–	3942
2022 Q4	$9.64K	Buy	+791	New	+$8.31K	﹤0.01%	4047
2022 Q3	–	Sell	-923	Closed	-$15K	–	4436
2022 Q2	$15K	Buy	+923	New	+$10.6K	﹤0.01%	4240
2021 Q3	–	Sell	-14,173	Closed	-$1.31M	–	2971
2021 Q2	$1.31M	Sell	14,173 -18,559	-57%	-$1.18M	0.01%	1381
2021 Q1	$1.7M	Buy	+32,732	New	+$1.54M	0.02%	1151
2015 Q2	–	Sell	-127	Closed	-$23K	–	1832
2015 Q1	$23K	Buy	+127	New	+$27.7K	﹤0.01%	1817

Other funds holding CARM

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DCM

Deuterium Capital Management Clearwater, Florida $86M AUM 87.31% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's CARM Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of Carisma Therapeutics (CARM) in Q1 2023, closing a stake of 791 shares — an estimated $9.64K sold.

Cubist Systematic Strategies first reported a position in CARM in Q1 2015 and held it in 5 quarters. The position peaked at $1.7M in Q1 2021. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

Cubist Systematic Strategies reported no remaining Carisma Therapeutics position as of Q1 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 791 Carisma Therapeutics shares in Q1 2023, an estimated $9.64K.
Cubist Systematic Strategies first reported a position in Carisma Therapeutics in Q1 2015 and held it in 5 quarters.
Cubist Systematic Strategies's Carisma Therapeutics position peaked at $1.7M in Q1 2021.
37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.